TPIV analysts say $1.50 coming! Check it out:
Tapimmune expects to sign up multiple partnerships for technology development and commercialization in large markets because “our technology has the potential to improve a variety of other technologies and approaches in the treatment of breast cancer and other infectious diseases, says Dr. Wilson. The company, he adds, expects to become a market leader in biotechnology “as we expect our continuing research to yield a pipeline of products.
Apart from a potential to make substantial returns from their investments, investors in the company should get the satisfaction that “their money would be directed to technologies which could alleviate pain and suffering caused by both the diseases and existing treatments.”
"When Tapimmune is recognized as an immunotherapy play along with the likes of Northwest BioTherapeutics (NWBO) and ImmunoCellular Therapeutics (IMUC), the market cap of Tapimmune is expected by some analysts to hit a market cap of $100 million, or a stock price of $1.50......"
Posts: 195 | From: Florida | Registered: Feb 2010
| IP: Logged |